Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.47 |
| ▸ | BRAF | P15056 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423907 | 0.87 | MAP2K1 (0.55) | MAP2K1BRAFKCNH2CYP2C9CYP2C19 | |
| SCHEMBL12423912 | 0.86 | MAP2K1 (0.56) | MAP2K1BRAFKCNH2CYP2C9CYP2C19 | |
| SCHEMBL12423792 | 0.86 | MAP2K1 (0.62) | MAP2K1KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12423784 | 0.86 | MAP2K1 (0.62) | MAP2K1KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12423803 | 0.84 | MAP2K1 (0.57) | MAP2K1BRAFKCNH2CYP2C9CYP2C19 | |
| SCHEMBL12423913 | 0.83 | MAP2K1 (0.47) | MAP2K1KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12423914 | 0.78 | MAP2K1 (0.75) | MAP2K1BRAFKCNH2CYP2C9CYP2C19 | |
| SCHEMBL5992819 | 0.75 | MAP2K1 (0.72) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL12423804 | 0.74 | MAP2K1 (0.75) | MAP2K1BRAFKCNH2CYP2C9CYP2C19 | |
| SCHEMBL12583459 | 0.72 | KCNH2 (0.56) | MAP2K1BRAFKCNH2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003025-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENENTECH, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | MAP2K7, MAP3K1, MAP3K5 | MAP2K1 11/4885BRAF 18/4885KCNH2 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.